

PRESS RELEASE

Lund 4 December 2018

Tumorad[®] patent granted in Europe

Spago Nanomedical AB (publ) announce today that the European Patent Office (EPO) has granted the company's patent application comprising product protection for Tumorad[®].

Tumorad[®] is based on nanoparticles loaded with a radioisotope and holds potential to become a new treatment of cancer. Earlier this year the patent was approved in the USA.

The patent, with the title "Nanostructures and applications thereof" (patent number 3122383) is valid until 2035.

The approval means that Spago Nanomedical holds product protection for Tumorad[®] in the two largest markets for radionuclide therapies, USA and Europe. Further approvals in other territories, including Japan, are pending.

For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 81188, mats.hansen@spagonanomedical.se.

Spago Nanomedical (Spotlight Stock Market, Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company's development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad[®]-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.

Tumorad[®] is a new type of radionuclide therapy based on Spago Nanomedical's proprietary nanoparticles and a therapeutically relevant radioisotope for tumor selective radiation therapy of cancer. Access to new therapies is essential for effective treatment of many forms of cancer. Tumorad[®] holds potential for treatment of aggressive and inaccessible tumors, as monotherapy or in synergy with other treatment types.

The information in this press release is such that Spago Nanomedical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU, 596/2014). The information was submitted for publication, through the agency of the contact person set out above, on 4 December, 2018.

For further information, see www.spagonanomedical.se.